The Carlyle Group said Monday that José (Joe) E. Almeida has joined the firm as an Operating Executive in the Global Healthcare group, effective immediately. Almeida was the former Chairman, President and CEO of Covidien which was sold to Medtronic plc in January for $50 billion.
Washington, DC – Global alternative asset manager The Carlyle Group (NASDAQ: CG) today announced that José (Joe) E. Almeida, former Chairman, President and CEO of Covidien, will join the firm as an Operating Executive in the Global Healthcare group, effective immediately. Mr. Almeida was instrumental in the sale of Covidien to Medtronic plc in January 2015 for $50 billion, creating the leading global medical device manufacturing company.
As an Operating Executive, Mr. Almeida will provide strategic guidance and advice to Carlyle professionals and portfolio company executives on the healthcare industry. In particular, he brings a wealth of experience to Carlyle’s global investment efforts in medical technology, in vitro diagnostics, life science tools, and pharmaceutical products and services. Mr. Almeida joins a group of more than 25 senior business executives – with an average of more than 40 years of experience – who help Carlyle to invest wisely and create value across a range of industries. Mr. Almeida will also continue to devote time to various roles outside of the firm.
Stephen H. Wise, Carlyle Managing Director and Co-head of the Global Healthcare team, said,
“Joe is a proven leader in the global healthcare industry with deep sector knowledge and significant experience operating in local markets around the world. He will be a great resource to our investment professionals as we evaluate new opportunities as well as to our portfolio executive teams, including Ortho Clinical Diagnostics where Joe is a member of the Board of Directors.”
Mr. Almeida said, “I am excited to partner with the Carlyle healthcare team as they search globally for investment opportunities. Carlyle’s global reach and industry expertise can be combined with my deep operational and managerial experience to form differentiated views as healthcare investors, and ultimately create value for their fund investors.”
Since inception, Carlyle has invested approximately $7 billion of equity in more than 40 transactions in the healthcare space, including Rede D’Or, Ortho Clinical Diagnostics, PPD, Qualicorp, Healthscope, HCR ManorCare and Multiplan.
Mr. Almeida joined Tyco Healthcare, the predecessor to Covidien, in 1995 where he served across multiple roles, including as President and CEO since 2011 and Chairman of the Board since 2012. Prior to being appointed CEO, Mr. Almeida was President of the Medical Devices organization at Covidien and he previously held leadership positions at Greatbatch Technologies, Inc., American Home Products’ Acufex Microsurgical division and Johnson & Johnson’s Professional Products division.
He served as Chairman of the Advanced Medical Technology Association (AdvaMed) Board of Directors, and he is currently on the Board of Directors of Ortho Clinical Diagnostics, State Street Corporation, EMC, and Analog Devices.
Mr. Almeida earned his BS in mechanical engineering from Escola de Engenharia Maua in São Paulo, Brazil.
* * * * *
About The Carlyle Group
The Carlyle Group (NASDAQ: CG) is a global alternative asset manager with $193 billion of assets under management across 130 funds and 156 fund of funds vehicles as of March 31, 2015. Carlyle’s purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions. Carlyle invests across four segments – Corporate Private Equity, Real Assets, Global Market Strategies and Investment Solutions – in Africa, Asia, Australia, Europe, the Middle East, North America and South America. Carlyle has expertise in various industries, including: aerospace, defense & government services, consumer & retail, energy, financial services, healthcare, industrial, real estate, technology & business services, telecommunications & media and transportation. The Carlyle Group employs more than 1,650 people in 40 offices across six continents.